Impact of Healthcare Insurance System Reform on the Pharmaceutical Wholesaling Business
First written in FY2016. 14 of 15 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「If major, unforeseeable changes to the system are introduced in the future and circumstances arise that affect our group's business structure, our group's performance and financial condition may be affected.」
The company continues to identify as a risk the possibility that major changes to the system resulting from healthcare system reform may affect its business structure and performance. - FY2021RestatedAnnual report
「If major, unforeseeable changes to the system are introduced in the future and circumstances arise that affect our group's business structure, our group's performance and financial condition may be affected.」
The company continues to disclose the possibility that healthcare insurance system reform may affect its business structure and performance. - FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2019-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform. - FY2018RestatedAnnual report
「Healthcare insurance system reform is being advanced, and depending on its details, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected.」
The company continues to disclose the risk of the impact of healthcare insurance system reform on its pharmaceutical wholesale business. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform. - FY2018-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform. - FY2017-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact of healthcare insurance system reform. - FY2017-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk associated with healthcare insurance system reform. - FY2016First statedAnnual report
「Fiscal consolidation is an urgent issue, and healthcare insurance system reform is being advanced as part of that effort. Depending on the details of the reform, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected.」
The company identifies the details of healthcare insurance system reform associated with fiscal consolidation as an external-environment risk.